1. Mauro MJ, Baccarani M, Cervantes F, Lipton JH, Matloub Y, Sinha R, Stone RM. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol, 26(May 20 suppl): abstr 7009, 2008
2. Rousselot H, Facon T, Paquette R, Bleickardt E, Dejardin D, Kantarjian HM. Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standard-dose imatinib: 2-year follow-up data from START-R. J Clin Oncol, 26(May 20 suppl): abstr 7012, 2008
3. Benichou A, Khoury HJ, Corm S, Nicolini FE, Craig AR, Humphriss E, Cortes JE. Multicenter open label study of subcutaneous (SC) omacetaxine (OMA) in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation. J Clin Oncol, 26(May 20 suppl): abstr 7021, 2008
4. Verstovsek S, Kantarjian HM, Pardanani A, Thomas DA, Cortes JE, Mesa R, Hogan W, Redman J, Levy R, Vaddi K, Tefferi A. A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF). J Clin Oncol, 26(May 20 suppl): abstr 7004, 2008
5. Byrd JC, Castro JE, Flinn IW, Forero-Torres A, Kipps TJ, Heerema NA, Lin TS, Mu H, Tangri S, O'Brien S. Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): results from a phase I/II multicenter study. J Clin Oncol, 26(May 20 suppl): abstr 7003, 2008